Gilead Sciences, Inc.

GILD

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0000882095

D/E

on the D/E boundary of 370 graded peers in healthcare

rank 293 of 370; percentile 79.1; sampling error 2.5 points; lower is stronger

A B C D E

D/E, the sloth



Scoreboard	
Profitability	C percentile 43.5
Solvency	D/E percentile 79.4
Growth and financing	C percentile 53.3
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $59.0B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: short runway, distress
Inputs computable	9 of 14
Graded from	filings received through Feb 24, 2026 256 days before the rescan; latest periodic filing 10-Q received Oct 30, 2026
Last close	$166.87 2026-11-06; market equity $207.0B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as "Gilead," the "company," "we," "our" or "us") is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 43.5						
Gross profitability	39.3%	32.3%		34.1	365	2025-12-31
Return on invested capital	not computable	9.3%				

latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(2.6%)	(6.6%)	73.7	802	2025-12-31
Gross margin stability, five years	1.4 pts	2.8 pts	22.8	242	2025-12-31
Solvency, sleeve percentile 79.4					
Twelve-month failure probability	not computable	0.08%			
liabilities and a nearby cover-page share count are required at 2026-09-30					
Altman Z double-prime	not computable	(0.37)			
one or more required annual facts are missing					
Net debt to EBITDA	not computable	1.82x			
latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	1.55x	2.94x	79.4	828	2025-12-31
Growth and financing, sleeve percentile 53.3					
Revenue growth, three-year compound	2.6%	10.0%	65.2	412	2025-12-31
Free cash flow growth, three-year compound	4.3%	10.9%	62.1	96	2025-12-31
Reinvestment rate	(5.1%)	37.1%	71.2	105	2025-12-31
Asset growth, three years	(2.2%)	2.2%	57.0	696	2025-12-31
Net share issuance, one year	(0.3%)	2.5%	10.8	630	2026-02-13

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
288	Femasys Inc. (FEMY)	77.8	D/E	dilution, short runway
289	Protalix BioTherapeutics, Inc. (PLX)	78.0	D/E	
290	Whitehawk Therapeutics, Inc. (WHWK)	78.3	D/E	
291	Milestone Scientific Inc. (MLSS)	78.6	D/E	late filer
292	C4 Therapeutics, Inc. (CCCC)	78.9	D/E	dilution, short runway, fortress balance sheet
293	Gilead Sciences, Inc. (GILD)	79.1	D/E	
294	Personalis, Inc. (PSNL)	79.4	D/E	
295	Ironwood Pharmaceuticals Inc. (IRWD)	79.7	D/E	late filer, fortress balance sheet
296	Champions Oncology, Inc. (CSBR)	79.9	D/E	
297	Lucid Diagnostics Inc. (LUCD)	80.2	D/E	dilution
298	Merck & Co., Inc. (MRK)	80.5	D/E	

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	26.8%	(2.1%)	67
Distance from 52-week high	(4.4%)	(30.5%)	86
EBIT to enterprise value	4.4%	(1.5%)	76
Free cash flow yield	4.6%	(1.0%)	80

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Book value to price	0.06	0.29	20
Sales to price	0.14	0.30	34
Composite equity issuance, five years	(21.7%)	21.4%	7
Relative strength against the sector, log excess return	0.07	(0.19)	67

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 8 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	8 (10-Q received Oct 30, 2026)
Median daily dollar volume, 63 sessions	$822.3M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$29.4B	2025-12-31	2026-02-24	10-K	26-000006
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$6.2B	2025-12-31	2026-02-24	10-K	26-000006
3	assets	us-gaap:Assets	$59.0B	2025-12-31	2026-02-24	10-K	26-000006
4	operating income	us-gaap:OperatingIncomeLoss	$7.3B	2022-12-31	2025-02-28	10-K	25-000006
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$5.8B	2022-12-31	2025-02-28	10-K	25-000006
6	income tax	us-gaap:IncomeTaxExpenseBenefit	$1.2B	2022-12-31	2025-02-28	10-K	25-000006
7	total debt	us-gaap:LongTermDebt	$25.2B	2022-12-31	2024-02-23	10-K	24-000007
8	book equity	us-gaap:StockholdersEquity	$21.2B	2022-12-31	2024-02-23	10-K	24-000007
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$5.4B	2022-12-31	2023-02-22	10-K	23-000007
10	total debt	us-gaap:LongTermDebt	$26.7B	2021-12-31	2023-02-22	10-K	23-000007
11	book equity	us-gaap:StockholdersEquity	$21.1B	2021-12-31	2023-02-22	10-K	23-000007
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$5.3B	2021-12-31	2023-02-22	10-K	23-000007
13	net income	us-gaap:NetIncomeLoss	$8.5B	2025-12-31	2026-02-24	10-K	26-000006
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$10.0B	2025-12-31	2026-02-24	10-K	26-000006
15	assets	us-gaap:Assets	$59.0B	2024-12-31	2026-02-24	10-K	26-000006
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$28.8B	2024-12-31	2026-02-24	10-K	26-000006
17	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$6.3B	2024-12-31	2026-02-24	10-K	26-000006
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$27.1B	2023-12-31	2026-02-24	10-K	26-000006
19	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$6.5B	2023-12-31	2026-02-24	10-K	26-000006
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$27.3B	2022-12-31	2025-02-28	10-K	25-000006
21	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$5.7B	2022-12-31	2025-02-28	10-K	25-000006
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$27.3B	2021-12-31	2024-02-23	10-K	24-000007
23	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$6.6B	2021-12-31	2024-02-23	10-K	24-000007
24	depreciation amortization	us-gaap:Depreciation	$323.0M	2022-12-31	2025-02-28	10-K	25-000006
25	operating income	us-gaap:OperatingIncomeLoss	$7.6B	2023-12-31	2026-02-24	10-K	26-000006
26	interest expense	us-gaap:InterestExpense	$944.0M	2023-12-31	2024-02-23	10-K	24-000007

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	current assets	us-gaap:AssetsCurrent	$18.3B	2025-12-31	2026-02-24	10-K	26-000006
28	current liabilities	us-gaap:LiabilitiesCurrent	$11.8B	2025-12-31	2026-02-24	10-K	26-000006
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$563.0M	2025-12-31	2026-02-24	10-K	26-000006
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$10.8B	2024-12-31	2026-02-24	10-K	26-000006
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$523.0M	2024-12-31	2026-02-24	10-K	26-000006
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$8.0B	2023-12-31	2026-02-24	10-K	26-000006
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$585.0M	2023-12-31	2026-02-24	10-K	26-000006
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$9.1B	2022-12-31	2025-02-28	10-K	25-000006
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$728.0M	2022-12-31	2025-02-28	10-K	25-000006
36	depreciation amortization	us-gaap:Depreciation	$370.0M	2025-12-31	2026-02-24	10-K	26-000006
37	operating income	us-gaap:OperatingIncomeLoss	$10.0B	2025-12-31	2026-02-24	10-K	26-000006
38	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$9.8B	2025-12-31	2026-02-24	10-K	26-000006
39	income tax	us-gaap:IncomeTaxExpenseBenefit	$1.3B	2025-12-31	2026-02-24	10-K	26-000006
40	current assets	us-gaap:AssetsCurrent	$19.2B	2024-12-31	2026-02-24	10-K	26-000006
41	current liabilities	us-gaap:LiabilitiesCurrent	$12.0B	2024-12-31	2026-02-24	10-K	26-000006
42	assets	us-gaap:Assets	$62.1B	2023-12-31	2025-02-28	10-K	25-000006
43	assets	us-gaap:Assets	$63.2B	2022-12-31	2024-02-23	10-K	24-000007
44	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,241,420,528	2026-02-13	2026-02-24	10-K	26-000006
45	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,245,346,062	2025-02-21	2025-02-28	10-K	25-000006

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.